^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD22 positive

    i
    Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
    Entrez ID:
    933
    Related biomarkers:
    Expression
    20h
    Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: May 2028 --> May 2029 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection
    2d
    ALLight: Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=83, Recruiting, AstraZeneca
    Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    11d
    A041703: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=84, Recruiting, National Cancer Institute (NCI) | N=64 --> 84
    Enrollment change
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    15d
    Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. (clinicaltrials.gov)
    P2, N=30, Recruiting, Daihong Liu
    New P2 trial
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule)
    |
    TP53 mutation • CD22 positive
    |
    Epidaza (chidamide)
    21d
    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Charite University, Berlin, Germany
    New P3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    29d
    CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=100, Recruiting, Beijing Tongren Hospital
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    1m
    A041501: Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=310, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • ITGB1 (Integrin Subunit Beta 1)
    |
    CD20 positive • CD22 positive
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine
    2ms
    IntReALL BCP 2020 International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 (2023-509392-17-00)
    P2/3, N=765, Not yet recruiting, Charite Universitaetsmedizin Berlin KR
    New P2/3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    cytarabine • Blincyto (blinatumomab) • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • idarubicin hydrochloride • mitoxantrone • mercaptopurine • vindesine
    2ms
    Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin)
    3ms
    A041703: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=64, Suspended, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    4ms
    A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P4, N=44, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    5ms
    Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma. (PubMed, Front Immunol)
    The patient achieved short-term remission with bortezomib in combination with etoposide, dexamethasone, cyclophosphamide, and doxorubicin as first-line therapy. After disease progression, the patient received daratumumab combined with GemOx as second-line treatment but showed no response...The patient received CD19 and CD22 CAR-T therapies as the third-line treatment and achieved durable complete remission for more than one year with good tolerance. A patient with refractory PBL achieved durable complete remission after CD19 and CD22 CAR-T therapies, suggesting this treatment may be effective for patients with refractory or relapsing PBL.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Darzalex (daratumumab)